---
title: "Ipamorelin"
slug: "ipamorelin"
type: "compound"
category: "Body Composition"
url: "https://peptidesciencethailand.com/compounds/ipamorelin"
description: "A highly selective GH secretagogue that stimulates pituitary release without raising cortisol or prolactin. Standalone profile, dosing, and clinical evidence."
---
# Ipamorelin

*Selective GH Secretagogue, Precision Growth Hormone Pulse Stimulation*

**Category:** Body Composition  
**Format:** Lyophilized Vial  
**Amount:** 5mg  
**Purity:** >99% (HPLC)

## Overview

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, where Aib represents alpha-aminoisobutyric acid and D-2-Nal represents D-2-naphthylalanine. Developed by Novo Nordisk in the late 1990s, Ipamorelin emerged from systematic structure-activity relationship studies aimed at creating a growth hormone releasing peptide (GHRP) with maximum selectivity for growth hormone release and minimal effects on other pituitary hormones. The result is one of the most selective GH secretagogues identified, distinguished by its ability to stimulate growth hormone release without significantly elevating cortisol, prolactin, or aldosterone levels.

Ipamorelin acts as an agonist at the growth hormone secretagogue receptor (GHSR-1a), also known as the ghrelin receptor. This G-protein-coupled receptor is primarily expressed on somatotroph cells of the anterior pituitary gland, as well as in the hypothalamus, hippocampus, and peripheral tissues. Upon binding to GHSR-1a, Ipamorelin activates the Gq/11 signaling pathway, leading to phospholipase C activation, inositol trisphosphate generation, and intracellular calcium mobilization from the endoplasmic reticulum. The resulting calcium influx triggers the fusion of growth hormone-containing secretory granules with the somatotroph cell membrane, releasing GH into the pituitary portal circulation.

What distinguishes Ipamorelin from other GHRP compounds such as GHRP-6 and GHRP-2 is its remarkable selectivity. Comparative studies published in the European Journal of Endocrinology demonstrated that while GHRP-6 and GHRP-2 stimulate not only GH but also ACTH, cortisol, and prolactin release, Ipamorelin produces a dose-dependent GH release with negligible effects on these other hormonal axes at therapeutic doses. This selectivity is attributed to Ipamorelin's unique receptor binding kinetics: it has a slower association rate and longer receptor occupancy time compared to GHRP-6, which appears to favor selective somatotroph activation over broader pituitary stimulation.

The growth hormone releasing profile of Ipamorelin closely mimics natural GH pulsatility. In clinical pharmacology studies, subcutaneous Ipamorelin administration produces a robust GH pulse that peaks within 30-45 minutes and returns to baseline within 2-3 hours. This pulsatile pattern is critical because sustained GH elevation, as seen with exogenous GH administration, can lead to receptor desensitization, insulin resistance, and other adverse effects. By stimulating endogenous GH release in a physiological pulse pattern, Ipamorelin maintains the normal feedback regulation between GH, IGF-1, and somatostatin.

The downstream effects of Ipamorelin-stimulated GH release are mediated primarily through insulin-like growth factor 1 (IGF-1). GH acts on hepatocytes to stimulate IGF-1 production, which then exerts anabolic effects throughout the body. IGF-1 activates the IGF-1 receptor tyrosine kinase, triggering the PI3K/Akt and MAPK/ERK signaling cascades that promote protein synthesis, cellular proliferation, and inhibition of apoptosis. In skeletal muscle, this translates to enhanced myofibrillar protein synthesis and satellite cell activation. In bone, IGF-1 stimulates osteoblast differentiation and collagen synthesis, supporting bone mineral density maintenance.

Ipamorelin's effects on body composition have been extensively studied in both animal and human models. In preclinical studies, chronic Ipamorelin administration increased lean body mass and reduced fat mass in a dose-dependent manner without affecting food intake, distinguishing it from ghrelin and GHRP-6, which have orexigenic (appetite-stimulating) properties. Phase II clinical trials in patients recovering from abdominal surgery demonstrated accelerated recovery and nitrogen retention with Ipamorelin treatment, confirming its anabolic potential in catabolic states.

The compound also displays favorable effects on bone metabolism. Studies in ovariectomized rats, a model of postmenopausal osteoporosis, demonstrated that Ipamorelin administration increased bone mineral content, cortical bone thickness, and bone formation rate. These effects were attributed to GH/IGF-1-mediated osteoblast stimulation and appeared after 12 weeks of daily administration, suggesting that sustained protocols are necessary for skeletal effects.

Ipamorelin's pharmacokinetic profile is well characterized. Following subcutaneous injection, bioavailability is approximately 65-70% with rapid absorption, reaching peak plasma concentrations within 15-20 minutes. The elimination half-life is approximately 2 hours, making it suitable for once, twice, or three-times daily dosing depending on the desired GH stimulation profile. The peptide is primarily cleared through renal filtration and enzymatic degradation, with no active metabolites identified.

Safety studies have demonstrated a wide therapeutic margin for Ipamorelin. In dose-escalation clinical trials, doses up to 100 mcg/kg produced proportional GH increases without cortisol or prolactin elevations. Adverse effects were limited to mild injection site reactions and transient flushing. The compound does not appear to affect glucose homeostasis at standard doses, though GH's counter-regulatory effects on insulin sensitivity warrant monitoring during extended protocols.

Current research interest in Ipamorelin extends to its potential applications in sarcopenia, age-related GH decline, post-surgical recovery, and body composition optimization. Its selectivity profile makes it an attractive research tool for dissecting the specific contributions of GH pulsatility to various physiological endpoints without the confounding effects of cortisol and prolactin elevation seen with less selective secretagogues.

## Mechanism of Action

### Step 1: GHSR-1a Receptor Agonism

Ipamorelin binds with high affinity to the growth hormone secretagogue receptor (GHSR-1a) on anterior pituitary somatotroph cells. Its unique binding kinetics produce selective somatotroph activation without significant stimulation of corticotroph or lactotroph cells.

### Step 2: Gq/11 Signaling & Calcium Mobilization

GHSR-1a activation triggers the Gq/11-phospholipase C cascade, generating IP3 and mobilizing calcium from intracellular stores. The resulting calcium surge induces fusion of GH-containing secretory granules with the cell membrane.

### Step 3: Pulsatile GH Release

Growth hormone is released into the pituitary portal circulation in a physiological pulse pattern, peaking at 30-45 minutes post-administration and returning to baseline within 2-3 hours. This preserves normal GH-IGF-1-somatostatin feedback regulation.

### Step 4: Hepatic IGF-1 Production

Circulating GH acts on hepatocyte GH receptors, activating JAK2/STAT5 signaling to stimulate IGF-1 gene transcription and protein secretion. IGF-1 mediates the majority of GH's anabolic effects on peripheral tissues.

### Step 5: Anabolic Tissue Effects via IGF-1R

IGF-1 activates IGF-1 receptor tyrosine kinase in skeletal muscle, bone, and connective tissue. Downstream PI3K/Akt and MAPK/ERK signaling promotes protein synthesis, satellite cell activation, osteoblast differentiation, and inhibition of protein degradation pathways.

## Researched Benefits

### Selective GH Stimulation

Ipamorelin is one of the most selective growth hormone secretagogues identified, producing dose-dependent GH release without significantly affecting cortisol, prolactin, or aldosterone levels. This selectivity reduces the side effect profile associated with less selective GHRPs and allows targeted GH axis research.

### Body Composition Optimization

Preclinical and clinical studies demonstrate Ipamorelin's ability to increase lean body mass and reduce fat mass through GH/IGF-1-mediated anabolic signaling. Unlike GHRP-6, Ipamorelin does not significantly stimulate appetite, making it suitable for body composition studies without confounding orexigenic effects.

### Bone Mineral Density Support

Chronic Ipamorelin administration in animal models of osteoporosis increases bone mineral content, cortical thickness, and bone formation rate. These effects are mediated by GH/IGF-1 stimulation of osteoblast activity and collagen synthesis, with observable improvements after 12 weeks of consistent administration.

### Recovery & Tissue Repair

Phase II clinical trials in post-surgical patients demonstrated accelerated recovery and improved nitrogen balance with Ipamorelin treatment. GH-mediated protein synthesis supports tissue repair processes, including wound healing, muscle recovery, and connective tissue remodeling.

## Dosage & Administration

| Parameter | Detail |
| --- | --- |
| Protocol | 200-300mcg per administration, typically 1-3 times daily via subcutaneous injection |
| Route | Subcutaneous injection |
| Duration | 8-12 weeks per cycle |
| Cycle Notes | Ipamorelin is commonly administered 2-3 times daily to amplify natural GH pulses. Timing around sleep (before bed) and fasting states optimizes the GH response. Extended cycles of 8-12 weeks are typical, with 4-week rest periods between cycles to prevent receptor desensitization. Some protocols use lower doses (100-200mcg) for maintenance after initial higher-dose phases. |
| Reconstitution | Reconstitute with bacteriostatic water. Using a 5mg vial with 2mL bacteriostatic water yields 2500mcg/mL concentration. Inject slowly along the vial wall to avoid peptide denaturation. Store reconstituted solution refrigerated at 2-8°C and use within 28 days. |

> **Specialist note:** A specialist should evaluate GH/IGF-1 baseline levels, glucose metabolism, and relevant medical history before initiating Ipamorelin protocols. While Ipamorelin does not directly affect cortisol, the downstream effects of elevated GH on glucose homeostasis and fluid retention require monitoring, particularly in individuals with metabolic conditions or those taking diabetes medications.

## Compound Reference Data

| Property | Value |
| --- | --- |
| Format | Lyophilized Powder |
| Amount | 5mg per vial |
| Purity | >99% |
| Purity Method | HPLC (High-Performance Liquid Chromatography) |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| Molecular Weight | 711.85 g/mol |
| Storage | Store lyophilized powder at -20°C. Reconstituted solution at 2-8°C. Protect from light. |
| Appearance | White lyophilized powder |

## Medical Guidance

Ipamorelin stimulates endogenous growth hormone release, which has downstream effects on IGF-1 levels, glucose metabolism, and fluid balance. Individuals with diabetes, pre-diabetic conditions, active malignancies, or pituitary disorders require thorough medical evaluation. The compound's effects on GH/IGF-1 signaling may interact with insulin-sensitizing medications and growth-factor-dependent conditions.

## Frequently Asked Questions

### What is Ipamorelin and how does it differ from other GH secretagogues?

Ipamorelin is a synthetic pentapeptide that selectively stimulates growth hormone release through the GHSR-1a (ghrelin) receptor. Its primary distinction from other GH secretagogues like GHRP-6 and GHRP-2 is its remarkable selectivity: it produces robust GH release without significantly elevating cortisol, prolactin, or aldosterone. This selectivity results in a cleaner side effect profile and more targeted GH axis stimulation.

### How does Ipamorelin compare to CJC-1295/Ipamorelin combination?

Standalone Ipamorelin stimulates GH release through the GHSR-1a receptor (the amplitude of GH pulses), while CJC-1295 acts on the GHRH receptor (affecting the frequency and baseline of GH secretion). When used together, they produce synergistic GH elevation through complementary mechanisms. Standalone Ipamorelin is studied when researchers want to isolate the effects of GHSR-1a-mediated GH stimulation without the prolonged GH elevation produced by CJC-1295's DAC-modified half-life.

### Does Ipamorelin increase appetite like GHRP-6?

No. One of Ipamorelin's advantages over GHRP-6 is its lack of significant orexigenic (appetite-stimulating) effects. While GHRP-6 strongly activates hunger signaling through the ghrelin receptor in hypothalamic appetite centers, Ipamorelin's receptor binding kinetics appear to favor pituitary somatotroph stimulation without triggering the appetite pathways. This makes it more suitable for body composition research where appetite confounding is undesirable.

### What is the optimal timing for Ipamorelin administration?

Research protocols typically administer Ipamorelin during fasting states to maximize the GH response, as elevated blood glucose and insulin suppress GH secretion. Common timing includes morning upon waking (before eating), post-exercise, and before sleep (at least 2 hours after the last meal). The pre-sleep dose aligns with the natural nocturnal GH surge, potentially amplifying the largest physiological GH pulse.

### How long does it take to see effects from Ipamorelin?

The GH-releasing effect of Ipamorelin is acute, with peak GH levels occurring 30-45 minutes after subcutaneous injection. However, the downstream physiological effects develop over weeks. Body composition changes and recovery improvements are typically reported in research protocols after 4-8 weeks of consistent administration. Bone density effects require longer periods of 12 or more weeks, consistent with the timeline of bone remodeling cycles.

## Related Compounds

- /compounds/cjc-1295-ipamorelin
- /compounds/mk-677
- /compounds/tesamorelin